Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

VC Deals Analysis: Variety In Volume, But Lackluster Value In April

Executive Summary

It would have been difficult to beat March's unusual bumper harvest, which benefitted from Grail's near-$1bn round, but venture fundraising efforts in April were stymied by the absence of deals beyond the $50m mark.

You may also be interested in...



First MRI Scanner Designed For NICU Babies Gets US Clearance

Israel's Aspect Imaging has scored the first 510(k) for an MRI machine specifically designed to scan infants in neonatal intensive care units where radiowaves from traditional MRIs could risk interfering with other hospital equipment.

VC Deals Analysis: From Famine To Feast, 2017 Bloats With May Haul

The venture financing climate has been somewhat dull so far this year but the investment activity levels enjoyed a much-needed boost in May. The month's haul of transactions not only brought in the quantity – with the highest deal volume to date – but also quality, high-value rounds.

VC Deals Analysis: Big Boost From Bumper Round

It had been a slow start to the year but one unusually large financing round from cancer diagnostics company Grail means the first quarter of 2017 has now outpaced the performance from any in the previous four years.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT104826

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel